Universal varicella vaccination: Efficacy trends and effect on herpes zoster

International Journal of Toxicology

Volumn 24, Issue 4, 2005, Pages 205-213

  Goldman, Gary S ^a  

^a Medical Veritas International (MVI)   (United States)

Author keywords

Herpes Zoster Incidence; Varicella Vaccination; Varicella Vaccine Efficacy; Varicella Zoster Virus (VZV)

Indexed keywords

CHICKENPOX VACCINE;

ARTICLE; CHICKENPOX; COST EFFECTIVENESS ANALYSIS; GEOGRAPHIC DISTRIBUTION; HEALTH PROGRAM; HERPES ZOSTER; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; UNITED STATES; VARICELLA ZOSTER VIRUS; VIRUS REACTIVATION; WILD TYPE;

ADOLESCENT; ADULT; CALIFORNIA; CHICKENPOX; CHICKENPOX VACCINE; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FORECASTING; HERPES ZOSTER; HUMANS; IMMUNIZATION, SECONDARY; MASS IMMUNIZATION; RETROSPECTIVE STUDIES;

ANTELOPE; HERPES ZOSTER; HUMAN HERPESVIRUS 3;

EID: 23744442396     PISSN: 10915818     EISSN: 1092874X     Source Type: Journal    
DOI: 10.1080/10915810591000659     Document Type: Article

References (58)

1. Arvin, A. M. 1992. Cell-mediated immunity to varicella-zoster virus. J. Infect. Dis. 166(Suppl. 1):S35-S41.
2. Arvin, A. M. 1996. Varicella-zoster virus. Clin. Microbiol Rev. 9:361-381.
3. Arvin, A. M., C. M. Koropchak, and A. E. Wittek. 1983. Immunologic evidence of reinfection with varicella-zoster virus. J. Infect. Dis. 148:200-205.
4. Asano, Y. 1996. Varicella vaccine: The Japanese experience. J. Infect. Dis. 174(Suppl. 3):S310-S313.
5. Baker, D. 1999. Direct costs attributed to chickenpox and herpes zoster in British Columbia 1992 to 1996. Can. Commun. Dis. Rep. 25:100-104.
6. Brisson, M., and W. J. Edmunds. 2003. Varicella vaccination in England and Wales: Cost-utility analysis. Arch. Dis. Child. 88:862-864.
7. Brisson M., N. J. Gay, W. J. Edmunds, and J. J. Andrews. 2002. Exposure to varicella boosts immunity to herpes-zoster: Implications for mass vaccination against chickenpox. Vaccine 20:2500-2507.
8. Brunell, P. A., V. M. Novelle, S. V. Lipton, and B. Pollock. 1988. Combined vaccine against measles, mumps, rubella, and varicella. Pediatrics 81:779-784.
9. Burgess, M. 2002. National Center for Immunisation Research and Surveillance of Vaccine Preventable Diseases (NCIRS), NCIRS Newsletter, Dec. 3. Available online at http://www.ncirs.usyd.edu.au/newsltrs/newsletter.01.pdf
10. Centers for Disease Control and Prevention (CDC). 1996. Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 45(RR11):1-25.
11. Civen, R. H., and L. Mascola. 2004. Annual report of the Active Varicella Surveillance and Epidemiologic Studies Cooperative Agreement No. U66/CCU911165-10. County of Los Angeles Department of Health Services, Acute Communicable Disease Control and CDC Sep. 30, 2003 through Sep. 29, 2004. Obtained via Freedom of Information Act (FOIA).
12. Civen, R. H., T. J. Maupin, H.L. Xiao, J. F. Seward, A. O. Jumaan, and L. Mascola. 2003. A population-based study of herpes zoster (HZ) in children and adolescents post-varicella vaccine licensure. In The Proceedings of the 41st Annual meeting of IDSA. Infectious Diseases Society of America, San Diego, California; Oct 9-13; Abstract 896.
13. Civen, R. H., T. J. Maupin, H. L. Xiao, J. F. Seward, A. O. Jumaan, and L. Mascola. 2004. A population-based study of herpes zoster (HZ) in children and adolescents post-varicella vaccine licensure 2000-2003. In The 38th National Immunization Conference of CDC. Nashville, Tennesee; May 11, Abstract 5427. Available online at http://cdc.confex.com/cdc/nic2004/tech program/paper5427.htm Recorded presentation available online at http://cdc. confex.com/cdc/nic2004/ wrfredirect.cgi?paperid=5427.
14. Clements, D. A., S. P. Moreira, P. M. Coplar, C. L. Bland, and E. B. Walter. 1999. Post licensure study of varicella vaccine effectiveness in a day-care setting. Pediatr. Infect. Dis. J. 1999; 18:1047-1050.
15. Davis, M. M., M. S. Patel, and A. Gebremariam. 2004. Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. Pediatrics 114:786-792.
16. Deming, W. E. 1991. Out of crisis. Cambridge, MA: MIT Center for Advanced Engineering Study.
17. Donahue, J. G., J. E. Manson, and R. Platt. 1995. The incidence of herpes zoster. Arch. Intern. Med. 155:1607.
18. Dworkin, M. S., C. E. Jennings, J. Roth-Thomas, J. E. Lang, C. Stukenberg, and J. R. Loupkin. 2002. An outbreak of varicella among children attending preschool and elementary school in Illinois. Clin. Infect. Dis. 35:102-104.
19. Finger, R., J. P. Hughes, B. J. Meade, A. R. Pelletier, and C. T. Palmer. 1994. Age-specific incidence of chickenpox. Public Health Rep. 109:750-755.
20. Fuller-Thomson, E., and M. Minkler. 2001. American grandparents providing extensive childcare to their grandchildren: Prevalence and profile. Gerentologist 41:201-209.
21. Galil, K., E. Fair, N. Mountcastle, P. Britz, and J. Seward. 2002a. Younger age at vaccination may increase risk of varicella vaccine failure. J. Infect. Dis. 106:102-105.
22. Galil, K., B. Lee, T. Strine, C. Carraher., A. L. Baughman, M. Eaton, J. Montero, and J. Seward. 2002b. Outbreak of varicella at a day-care center despite vaccination. N. Engl. J. Med. 347:1909-1915.
23. Garnett, G. P., and B. T. Grenfell. 1992. The epidemiology of varicella-zoster virus infections: The influence of varicella on the prevalence of herpes zoster. Epidemiol. Infect. 108:513-528.
24. Gershon, A. A. 2002. Varicella vaccine-are two doses better than one? N. Engl. J. Med. 347:1962-1963.
25. Gershon, A. A., P. Larussa, S. Steinberg, N. Mervish, S. H. Lo, and P. Meier. 1996. The protective effect of immunologic boosting against zoster: An analysis in leukemic children who were vaccinated against chickenpox. J. Infect. Dis. 173:450-453.
26. Goldman, G. S. 2003a. Incidence of herpes zoster among children and adolescents in a community with moderate varicella vaccination coverage. Vaccine 21:4243-4249.
27. Goldman, G. S. 2003b. Varicella susceptibility and incidence of herpes zoster among children and adolescents in a community under active surveillance. Vaccine 21:4238-4242.
28. Goldman, G. S. 2003c. Using capture-recapture methods to assess varicella incidence in a community under active surveillance. Vaccine 21:4250-4255.
29. Goldman, G. S. 2005. Cost-benefit analysis of universal varicella vacination taking into account the closely related herpes-zoster epidemiology. Vaccine 23:3349-3355.
30. Guess, H. A., D. D. Broughton, L. J. Melton III, and L. T. Kurland. 1986. Population-based studies of varicella complications. Pediatrics 78 (Suppl.):723-727.
31. Hardegree, M. C., and J. A. Donlon. 1995. Center for Biologics Evaluation and Research (CBER) Approval Letter, Reference No. 93-0395 and 93-0440, Mar 17. Available online at http://www.fda.gov/cberapprovltr /varmer31795L.htm
32. Hook, E. B., and R. R. Regal. 1992a. Capture-recapture methods (letter). Lancet 229:742.
33. Hook, E. B., and R. R. Regal. 1992b. The value of capture-recapture methods even for apparent exhaustive surveys: The need for adjustment for source of ascertainment intersection in attempted complete prevalence studies. Am. J. Epidemiol. 135:1060-1067.
34. Hope-Simpson, R. E. 1965. The nature of herpes zoster: A long-term study and a new hypothesis. Proc. R. Soc. Med. 58:9-20.
35. Krause, P. R. 2001. Evidence for frequent reactivation of the Oka varicella strain in healthy vacinees. Arch. Virol. Suppl. 17:7-15.
36. Krause, P. R., and D. M. Klinman. 2000. Varicella vaccination: Evidence for frequent reactivation of the vaccine strain in healthy children. Nat. Med. 6:451-454.
37. LaPorte, R. E., D. J. McCarty, T. J. Songer, G. Bruno, and N. Tajima. 1993. Disease monitoring. Lancet 341:1416.
38. Lee, B. R., S. L. Feaver, C. A. Miller, C. W. Hedberg, and K. R. Ehresmann. 2004. An elementary school outbreak of varicella attributed to vaccine failure: Policy implications. J. Infect. Dis. 190:477-483.
39. McCarty, D. J., E. S. Tull, C. S. Moy, C. K. Kwoh, and R. E. LaPorte. 1993. Ascertainment corrected rates: Applications of capture-recapture methods. Int. J. Epidemiol. 22:556-565.
40. Maupin, T. J., G. S. Goldman, C. L. Peterson, and L. Mascola. 2001. Annual Summary, Varicella Surveillance Project, Los Angeles County Department of Health Services (LACDHS); CDC Cooperative, 2000 Agreement No. U66/CCU911165-10.
41. Maupin, T. J., G. S. Goldman, C. L. Peterson, and L. Mascola. 2002a. Annual Summary, Varicella Surveillance Project, Los Angeles County Department of Health Services (LACDHS); CDC Cooperative, 2001 Agreement No. U66/CCU911165-10.
42. Maupin, T. J., G. S. Goldman, C. L. Peterson, L. Mascola, F. J. Seward, and A. O. Jumaan. 2002b. Varicella susceptibility among adolescents in an active surveillance site. 36th National Immunization Conference of the CDC, May 1, Denver, CO.
43. Oxman, M. N. 1995. Immunization to reduce the frequency and severity of herpes zoster and its complications. Neurology 45(Suppl. 8):S41-S46.
44. Roche, P., C. Blumer, and J. Spencer. 2002. Surveillance of viral pathogens in Australia-varicella-zoster virus. Commun. Dis. Intell. 26:576-580.
45. Seward, J. 2002. Varicella vaccine and shingles. JAMA Lett. 287:2211-2212.
46. Seward, J. F., B. M. Watson, C. L. Peterson, L. Mascola, L, J. W. Pelosi, J. X. Zhang, T. J. Maupin, G. S. Goldman, L. J. Tabony, K. G. Brodovicz, A. O. Jumaan, and M. Wharton. 2002. Varicella disease after introduction of varicella vaccine in the United States, 1995-2000. JAMA 287:606-611.
47. Seward, J. F., J. X. Zhang, T. J. Maupin, L. Mascola, and A. O. Jumaan. 2004. Contagiousness of varicella in vaccinated cases. JAMA 299:704-708.
48. Solomon, B. A., A. G. Kaporis, A. T. Glass, S. I. Simon, and H. E. Baldwin. 1998. Lasting immunity to varicella in doctors study (L.I.V.I.D. study). J. Am. Acad. Dermatol. 38:763-765.
49. Spingarn, R. W., and J. A. Benjamin. 1998. Universal vaccination against varicella (letter). N. Engl. J. Med. 338:683.
50. Terada, K., U. Hirago, S. Kawano, and N. Kataoka. 1995. Incidence of herpes zoster in pediatricians and history of reexposure to varicella-zoster virus in patients with herpes zoster. Kansenshogaku Zasshi 69:908-912.
51. Thacker, S. B., and R. L. Berkelman. 1988. Public health surveillance in the United States. Epidemiol. Rev. 10:164-198.
52. Thomas, S. L., J. G. Wheeler, and A. J. Hall. 2002. Contacts with varicella or with children and protection against herpes zoster in adults: A case-control study. Lancet, 360:678-682 cited 2002 July 12. Available online at http://image.thelancet.com/extras/01art6088web.pdf
53. Thomas, S. L., and A. J. Hall. 2004. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect. Dis. 4:26-33.
54. Tugwell, B. D., L. E. Lee, H. Gillette, E. M. Lorber, K. Hedberg, and P. R. Cieslak. 2004. Chickenpox outbreak in a highly vaccinated school population. Pediatrics 113(3 Pt 1):455-459.
55. Vazquez, M., P. S. LaRussa, A. A. Gershon, S. P. Steinberg, K. Freudigman, and E. D. Shapiro. 2001. The effectiveness of the varicella vaccine in clinical practice. N. Engl. J. Med. 344:955-960.
56. Wack, R. P. 1998. More on varicella immunization. N. Engl. J. Med. 338:1927.
57. Weibel, R. E., B. J. Neff, B. J. Kuter, H. A. Guess, C. A. Rothenberger, A. J. Fitzgerald, K. A. Connor, and A. A. McLean, et al. 1984. N. Engl. J. Med. 310:1409-1415.
58. Yih, W. K., D. R. Brooks, S. M. Lett, A. O. Jumaan, Z. Zhang, K. M. Clements, and J. F. Seward. 2005. The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage. 1998-2003. BMC Public Health 5:68.